Upconversion nanoparticles-based lateral flow immunoassay for point-of-care diagnosis of periodontitis

2021 ◽  
Vol 334 ◽  
pp. 129673
Author(s):  
Wanghong He ◽  
Minli You ◽  
Zedong Li ◽  
Lei Cao ◽  
Feng Xu ◽  
...  
Keyword(s):  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Upconversion Nanoparticles

scholarly journals Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis

2020 ◽  
Vol 58 (9) ◽  
Author(s):  
Katharina Ziegler ◽  
Anca Rath ◽  
Christoph Schoerner ◽  
Renate Meyer ◽  
Thomas Bertsch ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Roc Curve ◽  
Point Of Care ◽  
Lateral Flow ◽  
Lyme Neuroborreliosis ◽  
Diagnostic Tools ◽  
Lateral Flow Immunoassay ◽  
Enzyme Linked Immunosorbent Assay ◽  
European Federation ◽  
Point Of Care Test

ABSTRACT Diagnosis of Lyme neuroborreliosis (LNB) is challenging, as long as Borrelia-specific intrathecal antibodies are not yet detectable. The chemokine CXCL13 is elevated in the cerebrospinal fluid (CSF) of LNB patients. Here, we compared the performances of the Euroimmun CXCL13 enzyme-linked immunosorbent assay (CXCL13 ELISA) and the ReaScan CXCL13 lateral flow immunoassay (CXCL13 LFA), a rapid point-of-care test, to support the diagnosis of LNB. In a dual-center case-control study, CSF samples from 90 patients (34 with definite LNB, 10 with possible LNB, and 46 with other central nervous system [CNS] diseases [non-LNB group]) were analyzed with the CXCL13 ELISA and the CXCL13 LFA. Classification of patients followed the European Federation of Neurological Societies (EFNS) guidelines on LNB. The CXCL13 ELISA detected elevated CXCL13 levels in all patients with definite LNB (median, 1,409 pg/ml) compared to the non-LNB controls (median, 20.7 pg/ml; P < 0.0001), with a sensitivity of 100% and a specificity of 84.8% (cutoff value, 78.6 pg/ml; area under the receiver operating characteristic [ROC] curve, 0.93). Similarly, the CXCL13 LFA yielded elevated CXCL13 levels in 31 patients with definite LNB (median arbitrary value, 223.5) compared to the non-LNB control patients (median arbitrary value, 0; P < 0.0001) and had a sensitivity and specificity of 91.2% and 93.5%, respectively (cutoff arbitrary value, 22.5; area under the ROC curve, 0.94). The correlation between the CXCL13 levels obtained by ELISA and LFA was strong (Spearman correlation coefficient r = 0.89; P < 0.0001). The CXCL13 ELISA and the CXCL13 LFA are comparable diagnostic tools for the detection of CXCL13 in the CSF of patients with definite LNB. The advantage of the CXCL13 LFA is the shorter time to result.

Point-Of-Care Clinical Evaluation of the Clungene® SARS-CoV-2 Virus IgG/IgM 15-minute rapid test cassette with the Cobas® Roche RT-PCR platform in patients with or without Covid-19

2021 ◽  
Author(s):  
Fadi Haddad ◽  
Christopher C Lamb ◽  
Ravina Kullar ◽  
George Sakoulas
Keyword(s):  
Symptom Onset ◽  
Serological Test ◽  
Point Of Care ◽  
Diagnostic Testing ◽  
Rapid Test ◽  
Lateral Flow ◽  
Added Value ◽  
Lateral Flow Immunoassay ◽  
Rt Pcr ◽  
Past Infection

Background: Covid-19 remains a pandemic with multiple challenges to confirm patient infectivity: lack of sufficient tests, accurate results, validated quality, and timeliness of results. We hypothesize that a rapid 15-minute Point-Of-Care serological test to evaluate past infection complements diagnostic testing for Covid-19 and significantly enhances testing availability. Method: A three arm observational study at Sharp Healthcare, San Diego, California was conducted using the Clungene® lateral flow immunoassay (LFI) and compared with the Cobas® Roche RT PCR results. Arm 1: Thirty-five (35) subjects with confirmed Covid-19 using RT-PCR were tested twice: prior to 14 days following symptom onset and once between 12 and 70 days. Arm 2: Thirty (30) subjects with confirmed Covid-19 using RT-PCR were tested 12-70 days post symptom onset. Arm 3: Thirty (30) subjects with a negative RT-PCR for Covid-19 were tested 1-10 days following the RT-PCR test date. Results: Specificity of confirmed negative Covid-19 by RT-PCR was 100% (95% CI, 88.4%-100.0%); meaning there was 100% negative positive agreement between the RT-PCR and the Clungene® serological test results. Covid-19 subjects tested prior to day 7 symptom onset were antibody negative. In subjects 7-12 days following symptom onset with a confirmed positive Covid-19 by RT-PCR, the combined sensitivity of IgM and IgG was 58.6% (95% CI, 38.9%-76.5%). In subjects 13-70 days following symptom onset with a confirmed positive Covid-19 by RT-PCR the combined sensitivity of IgM and IgG was 90.5% (95% CI, 80.4%-96.4%). Conclusion: The Clungene® lateral flow immunoassay (LFI) is a useful tool to confirm individuals with an adaptive immune response to SARS-CoV-2 indicating past infection. Providing Point-Of-Care results within 15 minutes without any laboratory instrumentation or specialized software has an added value of increasing test availability to patients who have been symptomatic for more than one week to confirm past infection. Performance characteristics are optimal after 13 days with a sensitivity and specificity of 90% and 100%, respectively.

A glass fiber sheet-based electroosmotic lateral flow immunoassay for point-of-care testing

Lab on a Chip ◽  
2012 ◽  
Vol 12 (24) ◽  
pp. 5155 ◽  
Author(s):  
Yuriko Oyama ◽  
Toshihisa Osaki ◽  
Koki Kamiya ◽  
Ryuji Kawano ◽  
Tsutomu Honjoh ◽  
...  
Keyword(s):  
Glass Fiber ◽  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Point Of Care Testing ◽  
Fiber Sheet

scholarly journals Deeply-Dyed Nanobead System Based Lateral Flow Assay for Rapid Point-of-Care Drug Testing

2021 ◽  
Author(s):  
Lingzhi Fan ◽  
Jianbing Wu ◽  
Jing Yang ◽  
Fugang Li ◽  
Wannian Yan ◽  
...  
Keyword(s):  
Drug Testing ◽  
Social Impact ◽  
Hair Sample ◽  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Core Shell ◽  
Specific System ◽  
Naked Eye ◽  
Hair Samples

AbstractPoint-of-care test (POCT), which allows for rapid and sensitive screening of drugs abuse, is essential and can significantly reduce the clinical, economic and social impact of the opioid crisis worldwide. However, the traditional gold nanoparticle-based lateral flow immunoassay strip is not sensitive enough for detection of trace drugs in hair sample. Herein, we aimed to develop a more specific system using a composite polymer-based nanobead that is deeply dyed with phthalocyanine or similar oil soluble dyes, and termed as deeply dyed nanobead (DDNB). The prepared composite nanobeads displayed a clear core-shell structure and the core/shell ratios were readily controlled by polymer/dye feeding ratios. The absorbance stable nanobeads capped with carboxyl groups were covalently conjugated with antibodies, and were employed for preparation of lateral flow immunoassay strips for sensitive detection of drugs in hair with naked eye. The developed platform allows the detection of drugs such as morphine and methamphetamine in hair samples within 13 min (including hair sample processing ∼5 min). The cut-off value of DDNB strip for methamphetamine detection with naked eye is down to concentration of 8.0 ng/mL, which is about 3.1 times more sensitive than the traditional gold nanoparticles based lateral flow immunoassay. Moreover, the colorful DDNB system has the potential for multiplexing detection of analytes at point-of-care settings and with low cost.

scholarly journals Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care Samples

2020 ◽  
Author(s):  
Won Lee ◽  
Steven Straube ◽  
Ryan Sincic ◽  
Jeanne A. Noble ◽  
Juan Carlos Montoy ◽  
...  
Keyword(s):  
Predictive Value ◽  
Point Of Care ◽  
Acute Infection ◽  
High Specificity ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Onset Date ◽  
Rt Pcr ◽  
Serum Samples ◽  
Antibody Positivity

ABSTRACTIntroductionThe ongoing SARS-CoV-2 pandemic has spurred the development of numerous point of care (PoC) immunoassays. Assessments of performance of available kits are necessary to determine their clinical utility. Previous studies have mostly performed these assessments in a laboratory setting, which raises concerns of translating findings for PoC use. The aim of this study was to assess the performance of a lateral flow immunoassay for the detection of SARS-CoV-2 antibodies using samples collected at PoC.MethodOne lateral flow immunoassay (Humasis® COVID-19 IgG/IgM) was tested. In total, 50 PCR RT-PCR positive and 52 RT-PCR negative samples were collected at PoC. Fifty serum specimens from Dec 2018 to Feb 2019 were used as controls for specificity. Serum samples collected between Dec 2019 to Feb 2020 were used as additional comparators. Clinical data including symptom onset date was collected from patient history and the medical record.ResultsThe overall sensitivity for the kit was 74% (95% CI: 59.7% -85.4%). The sensitivity for IgM and IgG detection >14 days after date of onset was 88% (95% CI: 68.8% -97.5%) and 84% (95% CI: 63.9% – 95.5%), with a negative predictive value (NPV) of 94% for IgM (95% CI: 83.5% - 98.8%) and 93% for IgG (95% CI: 81.8% - 97.9%). The overall specificity was 94% (95% CI: 83.5% - 98.8%). The Immunoglobulin specific specificity was 94% for IgM (95% CI: 83.5% - 98.8%) and 98% for IgG (95% CI: 89.4% - 100.0%), with a positive predictive value (PPV) of 88% for IgM (95% CI: 68.8% - 97.5%) and 95% for IgG (95% CI: 77.2% - 99.9%) respectively for samples collected from patients >14 days after date of onset. Specimen collected during early phase of COVID-19 pandemic (Dec 2019 to Feb 2020) showed 11.8% antibody positivity, and 11.3% of PCR-negative patients demonstrated antibody positivity.DiscussionHumasis® COVID-19 IgG/IgM LFA demonstrates greater than 90% PPV and NPV for samples collected 14 days after the onset of symptoms using samples collected at PoC. While not practical for the diagnosis of acute infection, the use of the lateral flow assays with high specificity may have utility for determining seroprevalence or seroconversion in longitudinal studies.

Sign in / Sign up

Export Citation Format

Share Document